At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of a randomised, phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib combined with everolimus in patients with metastatic renal cell carcinoma.
Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma
26th August 2015
Oncology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given